Evaxion Biotech ( ($EVAX) ) has issued an update. On October 17, 2025, Evaxion Biotech announced impressive results from a phase 2 trial of its ...

Known as VaxSeer, the model was developed by Massachusetts Institute of Technology scientists, MIT News reported. VaxSeer ...

Objective Response Rate as 12 out of 16 advanced melanoma patients had objective clinical responses, with 11 of the 12 responders continuing to respond at 24 months follow-upImmune activation observed ...

Evaxion Biotech ( ($EVAX) ) just unveiled an announcement. On October 13, 2025, Evaxion A/S announced that it will present comprehensive data from ...

Evaxion's sophisticated AI Immunology platform aims to outperform competitors in vaccine development, in both oncology and infectious diseases indications. The company has already established three ...

COPENHAGEN, Denmark, October 8, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, is launching a significant ...

Sometimes recombinant strains revert to their wild nature even after 13 generations of propagation.” Formulation is another very costly part of vaccine production. notes Uma, “The stability of ...

A child receives a dose of polio vaccine during a door-to-door vaccination campaign in Karachi on September 9 - Copyright AFP Rizwan TABASSUM A child receives a dose ...

DUBLIN--(BUSINESS WIRE)--The "Global Hepatitis B Virus (HBV) Vaccine Market (by End User, Composition, & Region): Insights and Forecast with Potential Impact of COVID-19 (2022-2027)" report has been ...

CEPI, the Coalition for Epidemic Preparedness Innovations, and the Houston Methodist Research Institute (HMRI), have today announced a partnership to combine cutting-edge artificial intelligence (AI) ...

Anthropic gave AI a dose of "evil" during training to help it resist bad behavior later on. The company said the method works like a vaccine to build resilience. Anthropic's research comes as AI ...